Molecular Oncology
Volume 2, Issue 2 , Pages 161-163 , August 2008

Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors

  • Jonathan C. Trent

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Sarcoma Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Suite FC11.3032, Houston, TX 77030, USA. Tel.: +1 713 792 2636; fax: +1 713 794 1934.

References 

  1. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Research. 2004;64:5913–5919
  2. Desai J, Shankar S, Heinrich MC, et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clinical Cancer Research. 2007;13:5398–5405
  3. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. Journal of Clinical Oncology. 2006;24:4764–4774
  4. Lasota J, Corless CL, Heinrich MC, et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Modern Pathology. 2008;
  5. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. Journal of Clinical Oncology. 2002;20:3898–3905
  6. Tamborini E, Pricl S, Negri T, et al. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene. 2006;25:6140–6146

☆ Funding Source: This work was supported by an institutional Physician-Scientist Award (JCT, AJFL), NIH/NCI grant 1K23CA109060-02 (JCT), The Amschwand Sarcoma Cancer Foundation (JCT), NIH TL1 RR 024147 from the Center of Clinical and Translational Sciences at The University of Texas-Houston Health Science Center (JCM), and NIH/NCI grant K12 CA090891 (JCM). The DNA Sequencing Core Facility is supported by an NCI Cancer Center Support Grant CA-16672.

☆☆ Conflicts of Interest: None to declare.

PII: S1574-7891(08)00061-6

doi: 10.1016/j.molonc.2008.05.002

Molecular Oncology
Volume 2, Issue 2 , Pages 161-163 , August 2008

Article Tools

* Image Usage & Resolution